Quantcast

Latest Monoclonal antibodies Stories

2014-09-18 04:21:05

Company Recently Initiated Phase II in Bullous Pemphigoid CAMBRIDGE, Mass. and HERZLIYA PITUACH, Israel, Sept. 18, 2014 /PRNewswire/ -- Immune Pharmaceuticals Inc. (NASDAQ: IMNP; "Immune" or "the Company") announces today that it has initiated the screening of patients for a Phase II proof of concept clinical trial exploring the safety and efficacy of bertilimumab in the treatment of ulcerative colitis (UC). Dr. Daniel Teper, Chairman and CEO of Immune comments: "Bertilimumab is...

2014-09-17 12:25:34

Improved Efficacy and Lower List Price than the Anti-TNFs Will Be the Key Drivers for Prescribing of Emerging Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 17, 2014 /PRNewswire/ -- Decision Resources Group finds that among Crohn's disease/ulcerative colitis (CD/UC) patients eligible for biologic therapy, only a proportion of patients currently receive a biologic. Surveyed gastroenterologists cite patients' discomfort with biological therapy as the...

2014-09-17 08:31:07

-Enhances Capabilities for the Precision Medicine in Immuno-oncology and Autoimmune Disease Areas- LOS ANGELES and LEIPZIG, Germany, Sept. 17, 2014 /PRNewswire/ -- ImaginAb, Inc. today announced that it has entered into an exclusive technology development partnership with Novotectid GmbH for the development of antibody-based imaging agents to image CD4+ positive immune T cells. "Our collaboration with Novotectid expands ImaginAb's capability to precisely diagnose and determine...

2014-09-16 12:31:31

SAN DIEGO, Sept. 16, 2014 /PRNewswire/ -- Denovo Biopharma, LLC, today announced that it has acquired enzastaurin, a late-stage oncology drug, from Eli Lilly and Company (NYSE: LLY). Denovo gains all rights to develop, manufacture and commercialize enzastaurin globally, including transfer of all intellectual property and other rights, data, and information. http://photos.prnewswire.com/prnvar/20140820/138306 Lilly developed enzastaurin in a variety of indications, including in...

2014-09-15 23:06:03

According to new report from BCC Research, the global market for bioengineered protein drugs was valued at $151.9 billion in 2013 and is expected to reach about $157 billion in 2014. (PRWEB) September 15, 2014 Wellesley, Mass., September 15, 2014 – BCC Research (http://www.bccresearch.com) reveals in its new report, GLOBAL MARKETS FOR BIOENGINEERED PROTEIN DRUGS, the global market for bioengineered protein drugs was valued at $151.9 billion in 2013 and is expected to reach about $157...

2014-09-15 04:21:19

NEW YORK, LONDON, BERLIN and PARIS, September 15, 2014 /PRNewswire/ -- SOURCE M/S. Reportstack

2014-09-11 04:21:10

- Currently no approved treatment options available for patients living with HS, a skin disease which impacts approximately 1 percent of the adult population worldwide1,2 COPENHAGEN, Denmark, Sept. 11, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results from a Phase 3 pivotal study demonstrating that HUMIRA(®) (adalimumab) is effective in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and...

2014-09-10 08:31:55

SAN DIEGO, Sept. 10, 2014 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (OTCQB: TELK), a clinical stage oncology drug development company, announced today it has entered into agreements with Memorial Sloan Kettering Cancer Center (MSK) and Juno Therapeutics (Juno) for the development of novel therapeutic products using antibody targeting sequences derived from the fully-human antibodies discovered using the Company's internally developed antibody discovery platform. Under the...

2014-09-09 08:32:54

Collaboration to Express Antibodies and Antigens based on Sutro's Technology Platform Xpress CF(TM) SAN FRANCISCO, Sept. 9, 2014 /PRNewswire/ -- Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies, today announced its collaboration with the laboratory of James Wells, Ph.D., professor and chair of the Department of Pharmaceutical Chemistry at UCSF, as part of the...

2014-09-08 12:24:27

TNF-Alpha Inhibitors--Including Sales Leader Humira--Accounted for Over 90 Percent of the Psoriatic Arthritis Market, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 8, 2014 /PRNewswire/ -- Decision Resources Group finds that the market for psoriatic arthritis (PsA) therapies will grow nearly 66 percent, increasing to $3.7 billion in 2023, owing to the continued uptake of premium-price biologics and novel therapies that are expected to launch during the 2013 to...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'